The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.